

**Johnson & Johnson PRD, a division of Janssen-Cilag**

**CONCERTA®**

**Prolonged-release tablets (18 mg, 27 mg, 36 mg and 54 mg)**

**Response to the 26 April 2011 Final Variation Assessment Report  
and Day 115 CMS comments**

**(Type II variation for Use of CONCERTA in Adults)**

**(Mutual Recognition Procedure, UK/H/0544/002/II/056)**

**Issue Report Date:** 20 May 2011  
**Document No.:** EDMS-ERI-25002657

---

**Confidentiality Statement**

The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is *privileged* or *confidential* and may not be further disclosed by them. These restrictions on disclosure will apply equally to *all* future information supplied to you which is indicated as *privileged* or *confidential*.

